Pharmaceutical

Hanmi and MEDiC ink cancer biomarker collaboration deal

The agreement will see MEDiC’s MCAT platform identify biomarkers to support the development of Hanmi’s clinical assets.

Oct 16, 2024 - 04:00
Hanmi and MEDiC ink cancer biomarker collaboration deal
The agreement will see MEDiC’s MCAT platform identify biomarkers to support the development of Hanmi’s clinical assets.
Read the original article

Tags:

Previous Article

Cell and gene therapy approvals drive paradigm change in manufacturing

Next Article

Lilly touts Omvoh’s superiority over J&J’s Stelara in Crohn’s

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Female surgeons have lower rates of long-term adverse outcomes than their male peers, study finds

Female surgeons have lower rates of long-term adverse o...

Aug 31, 2023

Amneal’s CREXONT gains FDA approval for Parkinson’s treatment

Amneal’s CREXONT gains FDA approval for Parkinson’s tre...

Aug 9, 2024

A young girl’s custom gene therapy hints at a framework for tailored rare disease treatments

A young girl’s custom gene therapy hints at a framework...

Jul 12, 2023